^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

BCR-ABL1 D276G

i
Other names: BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL, ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1
Entrez ID:
over1year
Differences in Variants in the Structural Domain of BCR-ABL1 Kinase between Chinese Han and Minority Patients with Chronic Myeloid Leukemia by Sanger Sequencing and Next-Generation Sequencing. (PubMed, Cytogenet Genome Res)
In conclusion, there is no significant difference in BCR-ABL1 KD mutations between Han and ethnic minority patients. NGS has a higher mutation detection rate than SS, and can detect compound variants and genes with lower mutation frequency that are not detected by SS.
Journal • Next-generation sequencing
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
BCR-ABL1 E255K • BCR-ABL1 F317L • BCR-ABL1 Y253H • BCR-ABL1 M244V • ABL1 T315I • BCR-ABL1 D276G • BCR-ABL1 F359I • BCR-ABL1 mutation • ABL1 E255K • BCR-ABL1 E459K • ABL1 D276G • ABL1 F317L • ABL1 Y253H • BCR-ABL1 F359 • BCR-ABL1 L387F
almost3years
Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports. (PubMed, J Med Case Rep)
In our two cases, BLIN + ponatinib combination therapy was highly effective for R/R Ph+ ALL without any incidence of severe adverse events. Further studies with larger cohorts are warranted to validate the safety and efficacy of this potent combination therapy.
Clinical • Journal • Combination therapy
|
CD19 (CD19 Molecule)
|
BCR-ABL1 G250E • CD19 expression • BCR-ABL1 D276G
|
dasatinib • imatinib • Iclusig (ponatinib) • Blincyto (blinatumomab)